RxDoctor Payments Data

Parvin Afshar, MD

Psychiatry · Irvine, CANPI 1437247335

Payments from drug & device makers

$10,341in general payments, 2019–2025

Across 436 payments — averaging $23.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$2K
  • Sunovion Pharmaceuticals Inc.$1K
  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Johnson & Johnson$831
  • Neurocrine Biosciences, Inc.$755
  • plus $4K from 22 others

What the payments were for

  • Food & beverage$10,341100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,341 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$23,484
Medicare patients
39
Services billed
273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZoloftSertraline Hcl11$8,772
Lurasidone Hcl12$6,028
Aripiprazole11$3,094
Bupropion XlBupropion Hcl137$1,635
Buspirone Hcl141$1,426
Ziprasidone Hcl21$1,400
Divalproex Sodium ErDivalproex Sodium28$1,068
Nefazodone Hcl11$782
Olanzapine35$732
Haloperidol22$437
Desvenlafaxine Succinate ErDesvenlafaxine Succinate15$396
Trazodone Hcl93$303
Gabapentin22$266
Escitalopram Oxalate57$246
Fluoxetine Hcl31$226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$34$5227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →